Last reviewed · How we verify

NCT06783998: RMS-OSAS

Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome

ENROLLING BY INVITATION Last updated 28 May 2025
What this trial tests

trial in Obstructive Sleep Apnea (OSAS) in 150 participants. Enrolling by invitation.

Timeline
15 May 2025
Primary endpoint
15 February 2026
15 April 2026

Quick facts

Lead sponsorTarsus University
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment150
Start date15 May 2025
Primary completion15 February 2026
Estimated completion15 April 2026
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Tarsus University

Who can join

18 and older, any sex, with Obstructive Sleep Apnea (OSAS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients. This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tarsus University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06783998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing